Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 16/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 15/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4319081 | 0.86 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3TACR1KCNH2 | |
| SCHEMBL4329725 | 0.83 | SLC6A4 (0.65) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4492480 | 0.79 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3TACR1KCNH2 | |
| Cadaverine Tartrate SCHEMBL4486562 | 0.76 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3TACR1KCNH2 | |
| SCHEMBL655062 | 0.76 | MBTPS1 (0.49) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL5244702 | 0.75 | SLC6A2 (0.42) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4314759 | 0.75 | SLC6A2 (0.42) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4491890 | 0.74 | SLC6A2 (0.53) | SLC6A4SLC6A2SLC6A3TACR1KCNH2 | |
| SCHEMBL6859708 | 0.74 | NR1D1 (0.55) | SLC6A4SLC6A2SLC6A3CYP2D6MBTPS1 | |
| SCHEMBL4495794 | 0.73 | SLC6A2 (0.62) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615648-B2 | Aminomethyl-azacycle derivatives as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080004330-A1 | Aminomethyl-Azacycle Derivatives as Inhibitors of Monoamine Uptake | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004330-A1 | Aminomethyl-Azacycle Derivatives as Inhibitors of Monoamine Uptake | SLC6A2, TPH1, SLC6A3 | SLC6A4 8/4885SLC6A2 1/4885SLC6A3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.